April 23, 2018

AAN Releases New Practice Guideline on Disease-Modifying Therapies for Multiple Sclerosis

Lead author Alexander Rae-Grant, MD, shares what’s new and notable


When Cleveland Clinic neurologist Alexander Rae-Grant, MD, unveiled the new American Academy of Neurology (AAN) practice guideline on disease-modifying therapies (DMTs) for adults with multiple sclerosis (MS) at the AAN annual meeting April 23, there was plenty to cover.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Large amounts of research have been published since the previous AAN guideline on the subject was issued in 2002, and the new recommendations are the culmination of a systematic review of the literature and other evidence by a panel of physicians, nurses and patients from the U.S. and Canada.

Consult QD sat down with Dr. Rae-Grant, who led the review process and guideline development, to learn key takeaways from the guideline and get a behind-the-scene glimpse of the undertaking. The full guideline was simultaneously published in Neurology.

Q: To start, was there something noteworthy about the process of creating this guideline?

A: Some guidelines rely heavily on expert opinion. That was not the case here: Ours was a much more transparent and systematic process that stuck closely to the evidence. We strictly followed all the recommendations issued by the Institute of Medicine (now the National Academy of Medicine) for developing evidence-based guidelines. Each guideline recommendation is accompanied by a summary of the rationale used to come to a decision and a letter grade indicating the strength of the evidence. We had about as tight a process as possible, so I feel comfortable with our recommendations.

We also incorporated patient preferences in formulating recommendations, by relying on a survey of more than 5,000 people from the North American Research Committee on Multiple Sclerosis Registry. The survey solicited opinions on lifestyle priorities and the importance of various clinical outcomes, including those related to the safety and tolerability of medications. Shared decision-making is especially important in a disease such as MS, which involves considerable variability of treatment risks and benefits and disease course.


Q: Thirty recommendations were developed. What are some of the key ones?

A: Seventeen recommendations concern initiating therapy. Among these, a few should be highlighted:

  • Clinicians should counsel patients that DMTs are prescribed to try to slow long-term progression of disability, not to control immediate symptoms.
  • DMTs are recommended for patients with a single clinical demyelinating event and two or more brain lesions characteristic of MS. These criteria do not meet the 2010 International Criteria for MS, but evidence shows that DMTs are associated with a significant delay in development of MS in this setting.
  • For patients with a clinically isolated syndrome or a relapsing form of MS who do not choose to take a DMT, serial MRI is recommended at least annually so that a change in disease activity can be detected that might change the treatment strategy.
  • Use of alemtuzumab, fingolimod or natalizumab is recommended for highly active MS.
  • Ocrelizumab is recommended for patients with primary progressive MS who are ambulatory.

Ten recommendations deal with switching DMTs, which is a dilemma faced if it’s suspected that the current drug is not as effective as it should be. Clinicians should monitor MRI disease activity from the clinical outset to detect disease progression and inform treatment decisions. For a patient who has been using a DMT long enough for it take full effect, criteria for determining when to switch are any of the following over a one-year period of use:

  • One or more clinical relapses
  • Two or more unequivocally new MRI-detected lesions
  • Increased disability on examination

Three recommendations are devoted to stopping DMT. No good evidence is available that addresses whether, when or why to discontinue DMTs in a patient with relapsing-remitting MS who has no evidence of progression. Sometimes a third party, such as an insurer or health plan, may become involved in decisions about specific medications allowed. In such cases, clinicians should serve as an advocate for the patient as well as for the principle that only patients and doctors should determine appropriate therapy.

Finally, a controversial recommendation was that clinicians may advise discontinuing DMT for people with secondary progressive MS without ongoing relapses and who have not been ambulatory for at least two years. For such patients, disease activity is likely limited and the benefit of continued therapy low.


Q: Was there anything else controversial or surprising that you can share?

A: I was surprised that so many things I thought would not be controversial turned out to be! We took our mandate to keep to the evidence very seriously. We only recommended drugs for which we had evidence of benefit; if there were others in the same class with lack of supportive evidence, we did not include them in the recommendations. Understandably, proponents of some drugs did not always take the omission of those drugs lying down.

We did not address the hot topic in the field right now of so-called highly effective early treatment — i.e., using the strongest drugs up front, rather than the traditional approach of starting with the least toxic, standard medication and progressively increasing the strength and risk of therapy. The evidence for which strategy is better is not yet in, but it should be soon. This will certainly be addressed in the next guideline.

Related Articles

January 19, 2024
U.S. Suffers Significant Geographic Disparities in Access to Neurologists and Multiple Sclerosis Care

Analysis characterizes geography’s sizable role in urban/rural care divides

June 13, 2022
There’s a Gender Gap in Neurology Practice Guideline Development

New analysis details the disparities and points to opportunities for improvement

20-NEU-1963450 Benzil hero_650x450
November 12, 2020
Sexual Harassment in Neurosurgery: What the Numbers Reveal

In survey, both female and male respondents reporting ongoing concerns

October 12, 2020
AAN Position Statement on Stroke Presents Neurologists’ Views for Shaping Policy on Care Delivery

Group advocates for stroke systems of care supported by telestroke and proper reimbursement

20-NEU-1959736 Dr.-Gregory-Nemunaitis_650x450
October 1, 2020
New Medical Director of Spinal Cord Injury Rehab Embraces Teletraining

Dr. Gregory Nemunaitis looks to build on his history of integrating education, research and patient care

20-NEU-1909917 Women’s Alzheimer’s Prevention Center_CQD_650x450_CCC-1901608_06-03-20_0907
June 29, 2020
Newly Launched Alzheimer’s Center Is First in the Nation Focused Solely on Women

Mission centers on screening, prevention for at-risk women in their 30s to 60s

June 3, 2020
Shorter Door-to-Needle Time Means Better Long-Term Outcomes in Acute Ischemic Stroke

One-year results from national database confirm enduring benefits

inside a mobile stroke unit
May 8, 2020
Mobile Stroke Units: The Latest Research and What to Expect Next

Q&A with Dr. Andrew Russman, Medical Director of our Comprehensive Stroke Center